HEPATITIS B TREATMENT VACCINE ON THE BASIS OF INACTIVATED, FULLY RECOMBINANT HANSENULA CELLS EXPRESSING HBSAG

• 收藏
• 分享

专利权人:

WANG; Hemu

发明人:

WANG, Hemu,WANG, Changhua,YANG, Jun

申请号：

SG11201808266Q

公开号：

SG11201808266QA

申请日:

2017.03.16

申请国别(地区):

SG

年份:

2018

代理人:

摘要：

A hepatitis B treatment vaccine on the basis of inactivated, recombinant Hansenula cells expressing HBsAg. The vaccine is the HBsAg expressed in recombinant Hansenula cells. 10 8 cells contain 6-10µg HBsAg as an antigen； the vaccine contains a total of 16-21 HBsAg-specific CTL epitopes； the vaccine uses optimized inactivated, fully recombinant Hansenula cells as an adjuvant.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/